These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9577694)

  • 41. Single-center North American experience with wolf Piezolith 3000 in management of urinary calculi.
    Wang R; Faerber GJ; Roberts WW; Morris DS; Wolf JS
    Urology; 2009 May; 73(5):958-63. PubMed ID: 19278719
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Characteristics of the biochemical and radioimmunological diagnosis of urolithiasis of hyperparathyroid etiology].
    Tiktinskiĭ OL; Iarova NP; Sil'nitskiĭ PA; Korovin KF; Egor'kova AS
    Urol Nefrol (Mosk); 1985; (2):11-4. PubMed ID: 3992750
    [No Abstract]   [Full Text] [Related]  

  • 43. Urinary risk factors for recurrent calcium stone formation in Thai stone formers.
    Stitchantrakul W; Kochakarn W; Ruangraksa C; Domrongkitchaiporn S
    J Med Assoc Thai; 2007 Apr; 90(4):688-98. PubMed ID: 17487123
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolic evaluation of urolithiasis patients from eastern Croatia.
    Babić-Ivancić V; Avdagić SC; Serić V; Kontrec J; Tucak A; Füredi-Milhofer H; Marković M
    Coll Antropol; 2004 Dec; 28(2):655-66. PubMed ID: 15666597
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Urolithiasis in pediatric patients: a single center study of incidence, clinical presentation and outcome.
    VanDervoort K; Wiesen J; Frank R; Vento S; Crosby V; Chandra M; Trachtman H
    J Urol; 2007 Jun; 177(6):2300-5. PubMed ID: 17509344
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of comprehensive and limited metabolic evaluations in the treatment of patients with recurrent calcium urolithiasis.
    Yagisawa T; Chandhoke PS; Fan J
    J Urol; 1999 May; 161(5):1449-52. PubMed ID: 10210370
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The efficacy of dietary intervention on urinary risk factors for stone formation in recurrent calcium oxalate stone patients.
    Siener R; Schade N; Nicolay C; von Unruh GE; Hesse A
    J Urol; 2005 May; 173(5):1601-5. PubMed ID: 15821507
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Extracorporeal shock-wave lithotripsy in the treatment of urolithiasis of dystopic kidneys].
    Trapeznikova MF; Dutov VV
    Urologiia; 2006; (2):3-6. PubMed ID: 16708581
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Composition and characteristics of urinary calculi from guinea pigs.
    Hawkins MG; Ruby AL; Drazenovich TL; Westropp JL
    J Am Vet Med Assoc; 2009 Jan; 234(2):214-20. PubMed ID: 19210239
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The diagnostic significance of enzymuria in assessing kidney function in patients with urolithiasis].
    Neĭmark AI; Fidirkin AV; Zviagintsev EN; Zhukov VN
    Urol Nefrol (Mosk); 1997; (1):5-7. PubMed ID: 9123669
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Urinary microflora in calculous pyelonephritis and its role in recurrent stone formation].
    Liul'ko AV; Kropinov PI; Agafonov NV
    Vrach Delo; 1982 Jul; (7):67-70. PubMed ID: 7135910
    [No Abstract]   [Full Text] [Related]  

  • 52. [Food additive urisan in combined treatment of urolithiasis].
    Dzeranov NK; Konstantinova OV; Nikonova LM; Cherepanova EV; Drozhzheva VV
    Urologiia; 2009; (5):12-4. PubMed ID: 20213910
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Laboratory studies of 1,000 urinary calculi in patients with urolithiasis].
    Modliński L
    Pol Przegl Chir; 1974 Feb; 46(2):227-35. PubMed ID: 4817014
    [No Abstract]   [Full Text] [Related]  

  • 54. [Compliance and active cooperation of patients in preventing recurrence of urinary calculi].
    Hoffmann L; Becher R; Erdmann T
    Z Urol Nephrol; 1979 Apr; 72(4):269-75. PubMed ID: 463369
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolic evaluation: who, when and how often.
    De Coninck V; Keller EX; Traxer O
    Curr Opin Urol; 2019 Jan; 29(1):52-64. PubMed ID: 30325869
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term follow-up of recurrent stone-formers: who, how long and how often?
    Buchholz N; El-Husseiny T; Moraitis K; Maan Z; Masood J
    BJU Int; 2010 Jan; 105(1):1-2. PubMed ID: 19912208
    [No Abstract]   [Full Text] [Related]  

  • 57. [Urinary stone disease. Part IV. Recurrence prevention for urinary stone disease].
    Saenko VS; Gazimiev MA; Pesegov SV; Alyaev YG
    Urologiia; 2019 Jun; (2):88-96. PubMed ID: 31162908
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The methodology of remote monitoring of patients with urinary stone disease: development and primary approbation].
    Lebedev GS; Shaderkin IA; Gazimiev MA; Rudenko VI; I DV; Alfimov AE; Vladzimirsky AV; Gazimiev AM
    Urologiia; 2021 Nov; (5):26-34. PubMed ID: 34743428
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Pathogenesis of the phosphorus and calcium metabolic changes in urolithiasis].
    Timofeev SA
    Urol Nefrol (Mosk); 1980; (3):45-8. PubMed ID: 7385476
    [No Abstract]   [Full Text] [Related]  

  • 60. [The role of immunologic factors in the pathogenesis of urolithiasis].
    Ukhal' MI; Drannik GN
    Vrach Delo; 1990 Jan; (1):32-4. PubMed ID: 2330704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.